drugset / Trial / NCT00644124
Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the selected dose of aflibercept when it is combined with R-CHOP treatment (Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisone +/- intrathecal Methotrexate) administered every 2 weeks or every 3 weeks, in non Hodgkin B-cell lymphoma, and to determine how the body handles aflibercept when it is administered with R-CHOP.
Timeline
- Start
- 2008-03
- Primary completion
- 2011-10
- Completion
- 2011-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aflibercept | Protein / enzyme biologic | 2 mg/kg | Intravenous |
| Subject | Aflibercept | Protein / enzyme biologic | 3 mg/kg | Intravenous |
| Subject | Aflibercept | Protein / enzyme biologic | 4 mg/kg | Intravenous |
| Subject | Aflibercept | Protein / enzyme biologic | 6 mg/kg | Intravenous |
| Subject | Aflibercept | Protein / enzyme biologic | 8 mg/kg | Intravenous |